Merck's Keynote Falls Flat, And That's Just Fine

With yesterday's failure of Keytruda in head and neck cancer comes yet more evidence that not all anti-PD-1 agents were created equal. It also raises fresh questions about checkpoint inhibitor trial designs, and the precise role the US FDA now plays in overseeing the approval of these agents.

This is because Keytruda is already conditionally available for head and neck cancer, and the failed study in question, Keynote-040, might have served as the confirmatory trial to formalise approval; yet its failure is set to change nothing, at least if the signals Merck & Co. (NYSE:MRK) has sent the sellside are anything to go by.

This might not necessarily be down to a regulatory view that the use of anti-PD(NYSE:L)-1 agents across a vast swathe of cancer types should be strongly encouraged. But to strip a drug like Keytruda of an approval would be unusual for an FDA that seems to be loosening the straitjacket of approvability requirements, for cancer drugs at least.

READ FULL ARTICLE HERE